Return to Clinical Trials Search Results

Phase III, Double-blind, Randomized Placebo-controlled Study to Evaluate the Effects of Dalcetrapib on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS)

Primary Outcome Measures: The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce the occurrence of fatal and non-fatal myocardial infarction in subjects with a documented recent ACS and the AA genotype at variant rs1967309 in the ADCY9 gene. Secondoary Outcome Measures: Secondary objectives of this trial are to evaluate the potential of dalcetrapib to reduce the risk of: First occurrence of the composite of all-cause death, resuscitated cardiac arrest, non-fatal MI, non-fatal stroke First and recurrent occurrences of the composite of all-cause death, resuscitated cardiac arrest, non-fatal MI, non-fatal stroke First and recurrent occurrences of fatal and non-fatal MI Another secondary objective of this trial is to assess the long-term safety profile of dalcetrapib in this population.

Primary Outcome Measures: The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce the occurrence of fatal and non-fatal myocardial infarction in subjects with a documented recent ACS and the AA genotype at variant rs1967309 in the ADCY9 gene. Secondoary Outcome Measures: Secondary objectives of this trial are to evaluate the potential of dalcetrapib to reduce the risk of: First occurrence of the composite of all-cause death, resuscitated cardiac arrest, non-fatal MI, non-fatal stroke First and recurrent occurrences of the composite of all-cause death, resuscitated cardiac arrest, non-fatal MI, non-fatal stroke First and recurrent occurrences of fatal and non-fatal MI Another secondary objective of this trial is to assess the long-term safety profile of dalcetrapib in this population.